B
4.02
-0.10 (-2.43%)
| Previous Close | 4.12 |
| Open | 4.10 |
| Volume | 169,516 |
| Avg. Volume (3M) | 533,411 |
| Market Cap | 74,189,096 |
| Price / Earnings (TTM) | 50.25 |
| Price / Sales | 11.68 |
| Price / Book | 15.81 |
| 52 Weeks Range |
| Profit Margin | 20.58% |
| Operating Margin (TTM) | 5.32% |
| Diluted EPS (TTM) | 0.080 |
| Quarterly Revenue Growth (YOY) | 5.80% |
| Quarterly Earnings Growth (YOY) | -36.70% |
| Total Debt/Equity (MRQ) | 75.55% |
| Current Ratio (MRQ) | 2.26 |
| Operating Cash Flow (TTM) | 2.51 M |
| Levered Free Cash Flow (TTM) | 1.43 M |
| Return on Assets (TTM) | 8.44% |
| Return on Equity (TTM) | 31.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Bearish |
| Medical Care Facilities (Global) | Mixed | Bearish | |
| Stock | Basel Medical Group Ltd Ordinar | - | - |
AIStockmoo Score
-0.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.13 |
|
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 67.81% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Apr 2025 | Announcement | Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia |
| 19 Mar 2025 | Announcement | Basel Medical Group Ltd Announces Exercise of Overallotment Option |
| 03 Mar 2025 | Announcement | Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |